25 XP   0   0   10

Zelira Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse Zelira Therapeutics Ltd together

PenkeI guess you are interested in Zelira Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zelira Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Zelira Therapeutics Ltd

I send you an email if I find something interesting about Zelira Therapeutics Ltd.

Quick analysis of Zelira Therapeutics Ltd (30 sec.)










What can you expect buying and holding a share of Zelira Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$-0.18
Expected worth in 1 year
A$-4.21
How sure are you?
20.5%

+ What do you gain per year?

Total Gains per Share
A$-4.04
Return On Investment
-577.0%

For what price can you sell your share?

Current Price per Share
A$0.70
Expected price per share
A$0.69 - A$0.85
How sure are you?
50%

1. Valuation of Zelira Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)

A$0.70

Intrinsic Value Per Share

A$-7.94 - A$-2.60

Total Value Per Share

A$-8.11 - A$-2.77

2. Growth of Zelira Therapeutics Ltd (5 min.)




Is Zelira Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?-$1.2m$22.2m-$8.7m-65.4%

How much money is Zelira Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$8.1m-$2.4m-$5.7m-70.2%
Net Profit Margin-21,475.2%-2,335.0%--

How much money comes from the company's main activities?

3. Financial Health of Zelira Therapeutics Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Zelira Therapeutics Ltd? (5 min.)

Welcome investor! Zelira Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of Zelira Therapeutics Ltd.

What can you expect buying and holding a share of Zelira Therapeutics Ltd?

First you should know what it really means to hold a share of Zelira Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Zelira Therapeutics Ltd is A$0.7. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zelira Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zelira Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$-0.18. Based on the TTM, the Book Value Change Per Share is A$-1.01 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zelira Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-1.96-280.3%-0.72-102.9%-0.17-23.8%-0.19-27.5%-0.09-13.5%
Usd Book Value Change Per Share-1.94-276.7%-0.66-94.1%-0.11-15.3%-0.01-0.9%0.00-0.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.94-276.7%-0.66-94.1%-0.11-15.3%-0.01-0.9%0.00-0.4%
Usd Price Per Share0.59-0.73-0.54-0.25-0.13-
Price to Earnings Ratio-0.07--1.44--0.99--2.58--5.83-
Price-to-Total Gains Ratio-0.30--29.06--2.26--10.14--209,148.16-
Price to Book Ratio-5.14--1.42-0.28-1.26-2.60-
Price-to-Total Gains Ratio-0.30--29.06--2.26--10.14--209,148.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.45661
Number of shares2190
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.66-0.01
Usd Total Gains Per Share-0.66-0.01
Gains per Quarter (2190 shares)-1,442.42-13.59
Gains per Year (2190 shares)-5,769.70-54.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-5770-57800-54-64
20-11539-115500-109-118
30-17309-173200-163-172
40-23079-230900-217-226
50-28848-288600-272-280
60-34618-346300-326-334
70-40388-404000-380-388
80-46158-461700-435-442
90-51927-519400-489-496
100-57697-577100-543-550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.03.00.00.0%0.011.00.00.0%0.019.00.00.0%0.039.00.00.0%11.068.02.013.6%
Book Value Change Per Share0.03.00.00.0%1.06.04.09.1%5.07.07.026.3%8.023.08.020.5%26.040.015.032.1%
Dividend per Share0.00.03.00.0%0.00.011.00.0%0.00.019.00.0%0.00.039.00.0%0.00.081.00.0%
Total Gains per Share0.03.00.00.0%1.06.04.09.1%5.07.07.026.3%8.023.08.020.5%26.040.015.032.1%

Fundamentals of Zelira Therapeutics Ltd

About Zelira Therapeutics Ltd

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Fundamental data was last updated by Penke on 2024-03-13 22:15:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Zelira Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Zelira Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -62,377.5% means that $-623.78 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zelira Therapeutics Ltd:

  • The MRQ is -62,377.5%. The company is making a huge loss. -2
  • The TTM is -21,475.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-62,377.5%TTM-21,475.2%-40,902.3%
TTM-21,475.2%YOY-2,335.0%-19,140.3%
TTM-21,475.2%5Y-4,229.9%-17,245.3%
5Y-4,229.9%10Y-6,417.6%+2,187.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-62,377.5%-171.8%-62,205.7%
TTM-21,475.2%-205.8%-21,269.4%
YOY-2,335.0%-262.1%-2,072.9%
5Y-4,229.9%-455.6%-3,774.3%
10Y-6,417.6%-589.0%-5,828.6%
1.1.2. Return on Assets

Shows how efficient Zelira Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • -1,057.0% Return on Assets means that Zelira Therapeutics Ltd generated $-10.57 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zelira Therapeutics Ltd:

  • The MRQ is -1,057.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -355.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1,057.0%TTM-355.7%-701.3%
TTM-355.7%YOY-10.2%-345.6%
TTM-355.7%5Y-64.6%-291.1%
5Y-64.6%10Y-56.6%-8.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,057.0%-12.5%-1,044.5%
TTM-355.7%-12.2%-343.5%
YOY-10.2%-11.2%+1.0%
5Y-64.6%-13.4%-51.2%
10Y-56.6%-14.7%-41.9%
1.1.3. Return on Equity

Shows how efficient Zelira Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • 0.0% Return on Equity means Zelira Therapeutics Ltd generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-3.6%+3.6%
TTM-3.6%YOY-10.9%+7.3%
TTM-3.6%5Y-9.7%+6.1%
5Y-9.7%10Y-18.3%+8.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.8%+15.8%
TTM-3.6%-15.7%+12.1%
YOY-10.9%-13.9%+3.0%
5Y-9.7%-18.3%+8.6%
10Y-18.3%-19.2%+0.9%

1.2. Operating Efficiency of Zelira Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Zelira Therapeutics Ltd is operating .

  • Measures how much profit Zelira Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of -6,099.8% means the company generated $-61.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zelira Therapeutics Ltd:

  • The MRQ is -6,099.8%. The company is operating very inefficient. -2
  • The TTM is -3,164.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6,099.8%TTM-3,164.8%-2,935.0%
TTM-3,164.8%YOY-2,513.7%-651.1%
TTM-3,164.8%5Y-1,324.2%-1,840.6%
5Y-1,324.2%10Y-2,441.5%+1,117.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6,099.8%-299.1%-5,800.7%
TTM-3,164.8%-210.1%-2,954.7%
YOY-2,513.7%-279.7%-2,234.0%
5Y-1,324.2%-459.9%-864.3%
10Y-2,441.5%-596.9%-1,844.6%
1.2.2. Operating Ratio

Measures how efficient Zelira Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 62.00 means that the operating costs are $62.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 61.998. The company is inefficient in keeping operating costs low. -1
  • The TTM is 30.958. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ61.998TTM30.958+31.040
TTM30.958YOY26.420+4.538
TTM30.9585Y12.626+18.333
5Y12.62610Y30.152-17.527
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ61.9982.861+59.137
TTM30.9583.193+27.765
YOY26.4203.615+22.805
5Y12.6265.560+7.066
10Y30.1527.396+22.756

1.3. Liquidity of Zelira Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Zelira Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.43 means the company has $0.43 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.428. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.769. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.428TTM0.769-0.341
TTM0.769YOY2.141-1.371
TTM0.7695Y4.983-4.214
5Y4.98310Y16.907-11.924
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4283.986-3.558
TTM0.7694.440-3.671
YOY2.1415.552-3.411
5Y4.9836.158-1.175
10Y16.9076.492+10.415
1.3.2. Quick Ratio

Measures if Zelira Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.15 means the company can pay off $0.15 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.149. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.100. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.149TTM0.100+0.049
TTM0.100YOY1.065-0.965
TTM0.1005Y2.370-2.271
5Y2.37010Y8.589-6.219
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1493.638-3.489
TTM0.1004.168-4.068
YOY1.0655.515-4.450
5Y2.3706.012-3.642
10Y8.5896.209+2.380

1.4. Solvency of Zelira Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Zelira Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zelira Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.62 means that Zelira Therapeutics Ltd assets are financed with 161.5% credit (debt) and the remaining percentage (100% - 161.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 1.615. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 0.578. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ1.615TTM0.578+1.037
TTM0.578YOY0.064+0.514
TTM0.5785Y0.133+0.445
5Y0.13310Y0.269-0.136
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6150.335+1.280
TTM0.5780.330+0.248
YOY0.0640.267-0.203
5Y0.1330.367-0.234
10Y0.2690.378-0.109
1.4.2. Debt to Equity Ratio

Measures if Zelira Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.043-0.043
TTM0.043YOY0.069-0.027
TTM0.0435Y0.052-0.009
5Y0.05210Y0.064-0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM0.0430.398-0.355
YOY0.0690.334-0.265
5Y0.0520.429-0.377
10Y0.0640.476-0.412

2. Market Valuation of Zelira Therapeutics Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Zelira Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -0.07 means the investor is paying $-0.07 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -0.058. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.075. Based on the earnings, the company is expensive. -2
  • The TTM is -1.442. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.058MRQ-0.075+0.017
MRQ-0.075TTM-1.442+1.367
TTM-1.442YOY-0.989-0.453
TTM-1.4425Y-2.583+1.141
5Y-2.58310Y-5.831+3.248
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.058-2.643+2.585
MRQ-0.075-2.418+2.343
TTM-1.442-2.742+1.300
YOY-0.989-4.123+3.134
5Y-2.583-6.257+3.674
10Y-5.831-6.478+0.647
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -1.146. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.474. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.384. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.146MRQ-1.474+0.328
MRQ-1.474TTM-1.384-0.090
TTM-1.384YOY-0.858-0.526
TTM-1.3845Y-2.482+1.098
5Y-2.48210Y-5.960+3.478
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.146-3.244+2.098
MRQ-1.474-2.939+1.465
TTM-1.384-3.478+2.094
YOY-0.858-5.592+4.734
5Y-2.482-8.473+5.991
10Y-5.960-8.881+2.921
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Zelira Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -5.14 means the investor is paying $-5.14 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -3.999. Based on the equity, the company is expensive. -2
  • The MRQ is -5.142. Based on the equity, the company is expensive. -2
  • The TTM is -1.420. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.999MRQ-5.142+1.143
MRQ-5.142TTM-1.420-3.722
TTM-1.420YOY0.280-1.700
TTM-1.4205Y1.264-2.683
5Y1.26410Y2.597-1.334
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.9992.124-6.123
MRQ-5.1422.041-7.183
TTM-1.4202.118-3.538
YOY0.2802.915-2.635
5Y1.2643.682-2.418
10Y2.5974.114-1.517
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Zelira Therapeutics Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Zelira Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.970-1.010-66%-0.164-94%-0.010-100%-0.005-100%
Book Value Per Share---0.1751.813-110%3.000-106%2.134-108%1.044-117%
Current Ratio--0.4280.769-44%2.141-80%4.983-91%16.907-97%
Debt To Asset Ratio--1.6150.578+179%0.064+2419%0.133+1114%0.269+500%
Debt To Equity Ratio---0.043-100%0.069-100%0.052-100%0.064-100%
Dividend Per Share----0%-0%-0%-0%
Eps---3.008-1.104-63%-0.255-92%-0.295-90%-0.145-95%
Free Cash Flow Per Share---0.153-0.211+39%-0.274+80%-0.154+1%-0.076-51%
Free Cash Flow To Equity Per Share---0.006-0.085+1301%-0.255+4117%-0.121+1906%-0.059+884%
Gross Profit Margin--1.0001.012-1%1.016-2%1.117-10%1.115-10%
Intrinsic Value_10Y_max---2.599--------
Intrinsic Value_10Y_min---7.937--------
Intrinsic Value_1Y_max---0.297--------
Intrinsic Value_1Y_min---0.776--------
Intrinsic Value_3Y_max---0.864--------
Intrinsic Value_3Y_min---2.361--------
Intrinsic Value_5Y_max---1.397--------
Intrinsic Value_5Y_min---3.969--------
Market Cap7943040.000-29%10212480.00012765600.000-20%9333072.000+9%16387669.172-38%19475356.767-48%
Net Profit Margin---623.775-214.752-66%-23.350-96%-42.299-93%-64.176-90%
Operating Margin---60.998-31.648-48%-25.137-59%-13.242-78%-24.415-60%
Operating Ratio--61.99830.958+100%26.420+135%12.626+391%30.152+106%
Pb Ratio-3.999+22%-5.142-1.420-72%0.280-1935%1.264-507%2.597-298%
Pe Ratio-0.058+22%-0.075-1.442+1828%-0.989+1223%-2.583+3353%-5.831+7696%
Price Per Share0.700-29%0.9001.125-20%0.823+9%0.385+134%0.206+337%
Price To Free Cash Flow Ratio-1.146+22%-1.474-1.384-6%-0.858-42%-2.482+68%-5.960+304%
Price To Total Gains Ratio-0.236+22%-0.303-29.064+9490%-2.260+646%-10.140+3246%-209148.159+69012284%
Quick Ratio--0.1490.100+49%1.065-86%2.370-94%8.589-98%
Return On Assets---10.570-3.557-66%-0.102-99%-0.646-94%-0.566-95%
Return On Equity----0.0360%-0.1090%-0.0970%-0.1830%
Total Gains Per Share---2.970-1.010-66%-0.164-94%-0.010-100%-0.005-100%
Usd Book Value---1295602.17413422761.522-110%22203268.541-106%19738028.851-107%10643340.927-112%
Usd Book Value Change Per Share---1.937-0.659-66%-0.107-94%-0.006-100%-0.003-100%
Usd Book Value Per Share---0.1141.183-110%1.957-106%1.392-108%0.681-117%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.962-0.720-63%-0.167-92%-0.193-90%-0.095-95%
Usd Free Cash Flow---1130011.905-1565319.961+39%-2029775.445+80%-1424897.561+26%-809233.127-28%
Usd Free Cash Flow Per Share---0.100-0.138+39%-0.179+80%-0.100+1%-0.049-51%
Usd Free Cash Flow To Equity Per Share---0.004-0.055+1301%-0.166+4117%-0.079+1906%-0.039+884%
Usd Market Cap5181244.992-29%6661600.7048327000.880-20%6087962.866+9%10689676.601-38%12703775.219-48%
Usd Price Per Share0.457-29%0.5870.734-20%0.537+9%0.251+134%0.134+337%
Usd Profit---22266161.350-8170776.552-63%-2435415.376-89%-2798886.917-87%-1562638.937-93%
Usd Revenue--35695.81385012.302-58%151390.513-76%237321.262-85%130503.520-73%
Usd Total Gains Per Share---1.937-0.659-66%-0.107-94%-0.006-100%-0.003-100%
 EOD+2 -6MRQTTM+11 -22YOY+12 -215Y+9 -2410Y+6 -27

4.2. Fundamental Score

Let's check the fundamental score of Zelira Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.058
Price to Book Ratio (EOD)Between0-1-3.999
Net Profit Margin (MRQ)Greater than0-623.775
Operating Margin (MRQ)Greater than0-60.998
Quick Ratio (MRQ)Greater than10.149
Current Ratio (MRQ)Greater than10.428
Debt to Asset Ratio (MRQ)Less than11.615
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-10.570
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Zelira Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.017
Ma 20Greater thanMa 500.733
Ma 50Greater thanMa 1000.819
Ma 100Greater thanMa 2000.885
OpenGreater thanClose0.730
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-12-31
Total Stockholder Equity 32,155032,155-35331,802031,802-34,143-2,341
Long-term Assets Other  -32,3390-32,339263-32,0760-32,07632,809733



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets3,229
Total Liabilities5,216
Total Stockholder Equity-2,341
 As reported
Total Liabilities 5,216
Total Stockholder Equity+ -2,341
Total Assets = 3,229

Assets

Total Assets3,229
Total Current Assets2,142
Long-term Assets1,088
Total Current Assets
Cash And Cash Equivalents 65
Net Receivables 680
Inventory 1,397
Total Current Assets  (as reported)2,142
Total Current Assets  (calculated)2,142
+/-0
Long-term Assets
Property Plant Equipment 313
Long-term Assets Other 733
Long-term Assets  (as reported)1,088
Long-term Assets  (calculated)1,045
+/- 42

Liabilities & Shareholders' Equity

Total Current Liabilities5,004
Long-term Liabilities212
Total Stockholder Equity-2,341
Total Current Liabilities
Short-term Debt 1,513
Accounts payable 3,491
Total Current Liabilities  (as reported)5,004
Total Current Liabilities  (calculated)5,004
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)212
Long-term Liabilities  (calculated)0
+/- 212
Total Stockholder Equity
Common Stock45,516
Retained Earnings -78,902
Accumulated Other Comprehensive Income 31,046
Total Stockholder Equity (as reported)-2,341
Total Stockholder Equity (calculated)-2,341
+/-0
Other
Cash and Short Term Investments 65
Common Stock Shares Outstanding 11,347
Liabilities and Stockholders Equity 3,229
Net Debt 1,660
Net Working Capital -2,862
Short Long Term Debt Total 1,725



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-12-312023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-30
> Total Assets 
1,251
6,909
6,909
8,542
8,542
0
0
9,884
10,023
11,093
11,093
26,451
26,451
31,015
31,015
9,272
9,272
1,791
1,791
1,399
1,399
7,346
7,346
3,547
3,547
1,483
1,483
695
695
1,013
1,013
875
875
769
769
1,431
1,431
1,224
1,224
1,079
1,078
933
933
780
780
529
529
408
408
201
201
88
88
3,908
3,908
7,967
7,967
7,510
7,510
6,314
6,314
4,850
4,850
3,515
3,515
34,930
34,930
0
35,789
0
42,850
0
39,366
0
41,851
37,701
37,701
35,008
35,008
33,891
33,891
3,229
3,22933,89133,89135,00835,00837,70137,70141,851039,366042,850035,789034,93034,9303,5153,5154,8504,8506,3146,3147,5107,5107,9677,9673,9083,90888882012014084085295297807809339331,0781,0791,2241,2241,4311,4317697698758751,0131,0136956951,4831,4833,5473,5477,3467,3461,3991,3991,7911,7919,2729,27231,01531,01526,45126,45111,09311,09310,0239,884008,5428,5426,9096,9091,251
   > Total Current Assets 
0
0
0
0
2,512
0
0
0
1,790
0
0
0
8,618
0
0
0
9,272
0
0
0
1,125
0
0
0
3,453
0
0
0
430
0
0
0
805
0
0
0
1,347
0
0
0
973
0
0
0
599
0
0
0
333
201
201
88
88
3,908
3,908
7,967
7,967
6,795
6,795
5,777
5,777
4,515
4,515
3,125
3,125
1,469
1,469
1,833
1,833
9,083
9,083
6,090
6,090
8,977
8,977
5,076
5,076
2,626
2,626
1,771
1,771
2,142
2,1421,7711,7712,6262,6265,0765,0768,9778,9776,0906,0909,0839,0831,8331,8331,4691,4693,1253,1254,5154,5155,7775,7776,7956,7957,9677,9673,9083,90888882012013330005990009730001,3470008050004300003,4530001,1250009,2720008,6180001,7900002,5120000
       Cash And Cash Equivalents 
0
0
0
0
2,152
0
0
0
1,460
0
0
0
1,962
0
0
0
229
0
0
0
1,094
0
0
0
2,708
0
0
0
343
0
0
0
788
0
0
0
1,279
0
0
0
969
0
0
0
598
0
0
0
325
185
185
56
56
3,801
3,801
7,868
7,868
6,612
6,612
5,686
5,686
4,410
4,410
3,073
3,073
1,195
1,195
0
1,697
0
8,641
0
4,971
0
7,611
2,746
2,746
134
134
146
146
65
651461461341342,7462,7467,61104,97108,64101,69701,1951,1953,0733,0734,4104,4105,6865,6866,6126,6127,8687,8683,8013,80156561851853250005980009690001,2790007880003430002,7080001,0940002290001,9620001,4600002,1520000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
5,375
0
0
0
0
0
0
0
0
0
0
0
619
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
78
78
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000787800000000000000000000000000000000619000000000005,375000000000000
       Net Receivables 
152
322
322
110
110
0
0
80
80
68
68
709
709
642
642
1,108
1,108
0
0
30
29
230
230
744
123
33
33
87
87
16
16
17
17
20
20
69
69
85
85
4
4
8
8
2
2
7
7
9
9
16
16
32
32
106
106
99
99
104
104
91
91
87
87
51
51
274
274
64
64
142
142
57
57
319
319
256
256
233
783
-9
-1
680
680-1-978323325625631931957571421426464274274515187879191104104999910610632321616997722884485856969202017171616878733331237442302302930001,1081,1086426427097096868808000110110322322152
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
5,583
208
4,337
4,337
3,677
3,677
37
37
1
3
0
0
1
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
72
0
0
0
194
0
0
373
116
550
550
105
98
0
0981055505501163730019400072000000000000000000000000000000000000000000031003137373,6773,6774,3374,3372085,58300000000000
   > Long-term Assets 
0
0
0
0
6,030
0
0
0
8,233
0
0
0
17,833
0
0
0
0
0
0
0
274
0
0
0
94
0
0
0
265
0
0
0
70
0
0
0
84
0
0
0
105
0
0
0
181
0
0
0
75
0
0
0
0
0
0
0
0
0
0
0
537
0
0
0
391
0
0
0
33,956
0
0
0
33,275
0
0
32,625
32,625
32,339
32,382
32,076
32,120
1,088
1,08832,12032,07632,38232,33932,62532,6250033,27500033,9560003910005370000000000075000181000105000840007000026500094000274000000017,8330008,2330006,0300000
       Property Plant Equipment 
199
4,061
4,061
4,974
4,974
0
0
7,039
7,177
7,904
7,904
17,811
17,811
18,814
18,814
0
0
0
0
274
274
4,457
4,457
94
94
89
89
68
68
81
81
70
70
79
79
84
84
82
82
105
105
140
140
181
181
75
75
75
75
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33
33
1,125
1,125
1,580
1,580
1,331
1,331
1,239
1,239
1,010
1,010
848
848
704
704
519
519
313
3135195197047048488481,0101,0101,2391,2391,3311,3311,5801,5801,1251,12533330000000000000075757575181181140140105105828284847979707081816868898994944,4574,457274274000018,81418,81417,81117,8117,9047,9047,1777,039004,9744,9744,0614,061199
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,747
30,747
0
30,747
0
30,747
0
30,747
0
30,747
30,747
30,747
30,747
30,747
30,747
30,747
0
030,74730,74730,74730,74730,74730,74730,747030,747030,747030,747030,74730,74700000000000000000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
715
715
537
537
335
335
358
358
220
220
0
350
0
0
0
167
0
0
0
64
0
0
0
43
0
043000640001670003500220220358358335335537537715715000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,369
32,116
0
1,279
0
1,201
0
1,123
0
1,045
967
31,714
889
31,636
811
31,558
0
031,55881131,63688931,7149671,04501,12301,20101,279032,1161,36900000000000000000000000000000000000000000000000000000000000000000
       Other Assets 
0
1,056
1,056
1,056
1,056
0
0
1,056
1,056
968
968
21
21
0
0
0
0
0
0
0
0
0
0
0
0
0
0
197
197
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
715
715
537
537
0
0
0
0
0
0
0
0
0
0
100
100
72
72
64
0
43
43
43
0
0
004343430647272100100000000000053753771571500000000000000000000000000001971970000000000000021219689681,0561,056001,0561,0561,0561,0560
> Total Liabilities 
690
317
317
252
252
0
0
143
143
197
197
11,576
11,576
20,061
20,061
24,116
24,116
7,558
7,558
123
123
179
179
1,069
1,069
97
97
41
41
100
100
214
214
312
312
79
79
35
35
38
38
38
38
30
30
28
28
50
50
31
31
290
290
577
577
71
71
89
89
99
99
577
577
407
407
663
663
0
1,242
0
1,126
0
1,536
0
2,031
2,011
2,011
2,622
2,622
1,884
2,179
5,216
5,2162,1791,8842,6222,6222,0112,0112,03101,53601,12601,242066366340740757757799998989717157757729029031315050282830303838383835357979312312214214100100414197971,0691,0691791791231237,5587,55824,11624,11620,06120,06111,57611,57619719714314300252252317317690
   > Total Current Liabilities 
690
317
317
252
252
0
0
143
143
197
197
8,030
8,030
17,062
17,062
24,116
24,116
7,558
7,558
123
123
179
179
271
271
97
97
41
41
100
100
214
214
312
312
79
79
35
35
38
38
38
38
30
30
28
28
50
50
31
31
290
290
577
577
71
71
89
89
99
99
577
577
407
407
661
661
670
670
648
648
1,076
1,076
936
936
1,627
1,627
2,261
2,261
1,884
1,884
5,004
5,0041,8841,8842,2612,2611,6271,6279369361,0761,07664864867067066166140740757757799998989717157757729029031315050282830303838383835357979312312214214100100414197972712711791791231237,5587,55824,11624,11617,06217,0628,0308,03019719714314300252252317317690
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
2,848
0
0
0
3,317
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
211
211
0
0
0
0
0
0
0
0
0
0
0
0
0
61
0
0
0
91
0
0
117
117
0
133
0
143
1,513
1,5131430133011711700910006100000000000002112110000000000000000000000000000000000003,3170002,848000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
211
211
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000021121100000000000000000000000000000000000000000000000000000
       Accounts payable 
97
0
0
57
57
0
0
59
59
171
171
2,692
2,692
8,877
8,877
18,646
18,646
7,452
7,452
98
98
167
167
212
212
88
88
41
41
100
100
214
214
312
312
79
79
35
35
38
38
38
38
30
30
28
28
50
50
31
31
290
290
366
366
71
71
89
89
99
99
577
577
407
407
638
638
559
559
602
602
985
985
818
818
1,510
1,510
2,127
2,127
1,741
1,741
3,491
3,4911,7411,7412,1272,1271,5101,510818818985985602602559559638638407407577577999989897171366366290290313150502828303038383838353579793123122142141001004141888821221216716798987,4527,45218,64618,6468,8778,8772,6922,69217117159590057570097
       Other Current Liabilities 
593
317
317
195
195
0
0
85
84
25
25
2,490
2,490
1,792
1,792
2,152
2,152
105
105
25
25
12
12
59
59
9
9
0
0
0
0
0
214
0
0
0
79
0
0
0
38
0
0
0
30
0
0
0
50
0
0
0
290
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
50
0
0
0
0
0
0
0
117
133
133
143
143
0
014314313313311700000005050000000000000002900005000030000380007900021400000995959121225251051052,1522,1521,7921,7922,4902,4902525848500195195317317593
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
3,546
0
0
0
0
0
0
0
0
0
0
0
798
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
571
0
0
0
461
0
0
384
384
0
361
0
295
212
21229503610384384004610005710000000000000000000000000000000000000000000798000000000003,546000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
571
0
478
0
461
0
416
0
384
0
361
0
295
0
029503610384041604610478057102000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
3,262
3,262
2,223
2,223
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000000000002,2232,2233,2623,26200000000000
> Total Stockholder Equity
561
6,592
6,592
8,290
8,290
8,290
0
9,741
9,879
10,897
10,897
14,876
14,875
10,954
10,954
0
-14,843
0
0
1,276
1,276
7,167
7,167
2,478
2,478
1,386
1,386
654
654
913
913
661
661
456
456
1,352
1,352
1,189
1,189
1,040
1,040
895
895
750
750
501
501
358
358
170
170
-203
-203
3,331
3,331
7,897
7,897
7,421
7,421
6,214
6,214
4,273
4,273
3,108
3,108
34,266
34,266
0
34,547
0
41,724
0
37,830
0
39,820
35,203
35,203
32,155
32,155
31,802
31,802
-2,341
-2,34131,80231,80232,15532,15535,20335,20339,820037,830041,724034,547034,26634,2663,1083,1084,2734,2736,2146,2147,4217,4217,8977,8973,3313,331-203-2031701703583585015017507508958951,0401,0401,1891,1891,3521,3524564566616619139136546541,3861,3862,4782,4787,1677,1671,2761,27600-14,843010,95410,95414,87514,87610,89710,8979,8799,74108,2908,2908,2906,5926,592561
   Common Stock
647
6,481
6,481
8,402
8,402
0
0
10,303
10,303
11,798
11,798
14,429
14,428
19,468
19,468
24,820
24,820
24,820
24,820
28,325
28,325
7,074
7,074
14,947
14,947
14,947
14,947
14,947
14,947
14,947
14,947
14,947
14,947
14,947
14,947
15,962
15,962
15,962
15,962
15,962
15,962
15,962
15,962
15,962
15,962
15,962
15,962
15,970
15,970
16,308
16,308
16,308
16,308
8,175
8,175
13,803
13,803
13,803
13,803
13,823
13,823
13,823
13,823
13,823
13,823
21,690
21,690
26,076
26,076
36,495
36,495
36,651
36,651
41,790
41,790
43,746
43,746
43,746
43,746
45,516
45,516
45,516
45,51645,51645,51643,74643,74643,74643,74641,79041,79036,65136,65136,49536,49526,07626,07621,69021,69013,82313,82313,82313,82313,82313,82313,80313,80313,80313,8038,1758,17516,30816,30816,30816,30815,97015,97015,96215,96215,96215,96215,96215,96215,96215,96215,96215,96215,96215,96214,94714,94714,94714,94714,94714,94714,94714,94714,94714,94714,94714,9477,0747,07428,32528,32524,82024,82024,82024,82019,46819,46814,42814,42911,79811,79810,30310,303008,4028,4026,4816,481647
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-27
0
0
0
-98
0
0
0
1,948
0
0
0
0
0
0
0
0
0
0
0
8,267
0
0
0
3,905
0
0
0
3,905
0
0
0
4,219
0
0
0
4,219
0
0
0
314
0
0
0
0
0
0
0
0
0
0
0
475
0
0
0
503
0
0
0
965
0
0
0
27,171
0
0
0
28,427
0
0
30,651
30,651
0
30,880
0
31,053
31,046
31,04631,053030,880030,65130,6510028,42700027,171000965000503000475000000000003140004,2190004,2190003,9050003,9050008,267000000000001,948000-98000-270000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
428
428
475
475
496
496
503
503
624
624
965
965
26,837
26,837
27,171
27,171
27,524
27,524
28,427
28,427
28,849
28,849
30,651
30,651
30,880
30,880
31,053
-570
0
0-57031,05330,88030,88030,65130,65128,84928,84928,42728,42727,52427,52427,17127,17126,83726,83796596562462450350349649647547542842800000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue301
Cost of Revenue-3,517
Gross Profit-3,216-3,216
 
Operating Income (+$)
Gross Profit-3,216
Operating Expense-4,197
Operating Income-7,413-7,413
 
Operating Expense (+$)
Research Development1,336
Selling General Administrative5,644
Selling And Marketing Expenses75
Operating Expense4,1977,055
 
Net Interest Income (+$)
Interest Income77
Interest Expense-77
Other Finance Cost-77
Net Interest Income-77
 
Pretax Income (+$)
Operating Income-7,413
Net Interest Income-77
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-7,412-7,414
EBIT - interestExpense = -7,489
-6,716
-5,496
Interest Expense77
Earnings Before Interest and Taxes (EBIT)-7,413-7,335
Earnings Before Interest and Taxes (EBITDA)-6,868
 
After tax Income (+$)
Income Before Tax-7,412
Tax Provision-0
Net Income From Continuing Ops-6,269-7,412
Net Income-5,573
Net Income Applicable To Common Shares-5,573
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses7,714
Total Other Income/Expenses Net177
 

Technical Analysis of Zelira Therapeutics Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zelira Therapeutics Ltd. The general trend of Zelira Therapeutics Ltd is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zelira Therapeutics Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Zelira Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.85 < 0.85 < 0.85.

The bearish price targets are: 0.69 > 0.69 > 0.69.

Tweet this
Zelira Therapeutics Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Zelira Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Zelira Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Zelira Therapeutics Ltd. The current macd is -0.03468621.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Zelira Therapeutics Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Zelira Therapeutics Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Zelira Therapeutics Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Zelira Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartZelira Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Zelira Therapeutics Ltd. The current adx is 15.03.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Zelira Therapeutics Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Zelira Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Zelira Therapeutics Ltd. The current sar is 0.6908.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Zelira Therapeutics Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Zelira Therapeutics Ltd. The current rsi is 38.02. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Zelira Therapeutics Ltd Daily Relative Strength Index (RSI) ChartZelira Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Zelira Therapeutics Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Zelira Therapeutics Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Zelira Therapeutics Ltd Daily Stochastic Oscillator ChartZelira Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Zelira Therapeutics Ltd. The current cci is -46.31294964.

Zelira Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartZelira Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Zelira Therapeutics Ltd. The current cmo is -21.45900593.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Zelira Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartZelira Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Zelira Therapeutics Ltd. The current willr is -84.61538462.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Zelira Therapeutics Ltd Daily Williams %R ChartZelira Therapeutics Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Zelira Therapeutics Ltd.

Zelira Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Zelira Therapeutics Ltd. The current atr is 0.02391873.

Zelira Therapeutics Ltd Daily Average True Range (ATR) ChartZelira Therapeutics Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Zelira Therapeutics Ltd. The current obv is 406,652.

Zelira Therapeutics Ltd Daily On-Balance Volume (OBV) ChartZelira Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Zelira Therapeutics Ltd. The current mfi is 38.01.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Zelira Therapeutics Ltd Daily Money Flow Index (MFI) ChartZelira Therapeutics Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Zelira Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Zelira Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Zelira Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.017
Ma 20Greater thanMa 500.733
Ma 50Greater thanMa 1000.819
Ma 100Greater thanMa 2000.885
OpenGreater thanClose0.730
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Zelira Therapeutics Ltd with someone you think should read this too:
  • Are you bullish or bearish on Zelira Therapeutics Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zelira Therapeutics Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zelira Therapeutics Ltd

I send you an email if I find something interesting about Zelira Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Zelira Therapeutics Ltd.

Receive notifications about Zelira Therapeutics Ltd in your mailbox!